Maturation but not survival of dopaminergic nigrostriatal neurons is affected in developing and aging BDNF-deficient mice

[1]  M. Abercrombie.  Estimation of nuclear population from microtome sections , 1946, The Anatomical record.

[2]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[3]  T. Jessell,et al.  Release of dopamine from dendrites in rat substantia nigra , 1976, Nature.

[4]  J. Coyle.  Biochemical aspects of neurotransmission in the developing brain. , 1977, International review of neurobiology.

[5]  J. Glowinski,et al.  Release of dopamine in vivo from cat substantia nigra , 1977, Nature.

[6]  T. Robbins,et al.  Depletion of unilateral striatal dopamine impairs initiation of contralateral actions and not sensory attention , 1985, Nature.

[7]  T. Schallert,et al.  Reactive capacity: A sensitive behavioral marker of movement initiation and nigrostriatal dopamine function , 1985, Brain Research.

[8]  D L Price,et al.  Parkinson's disease , 1985, Neurology.

[9]  S. File,et al.  Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: A novel test of anxiety in the rat , 1986, Pharmacology Biochemistry and Behavior.

[10]  S. Kish,et al.  Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.

[11]  H. Groenewegen,et al.  The pre- and postnatal development of the dopaminergic cell groups in the ventral mesencephalon and the dopaminergic innervation of the striatum of the rat , 1988, Neuroscience.

[12]  Yves-Alain Barde,et al.  Brain-derived neurotrophic factor increases survival and differentiated functions of rat septal cholinergic neurons in culture , 1990, Neuron.

[13]  F. Hefti,et al.  Promotion of central cholinergic and dopaminergic neuron differentiation by brain-derived neurotrophic factor but not neurotrophin 3. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[14]  G. Yancopoulos,et al.  BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra , 1991, Nature.

[15]  S. Walsh,et al.  Motor impairments after methamphetamine-induced neurotoxicity in the rat. , 1992, The Journal of pharmacology and experimental therapeutics.

[16]  R. Lindsay,et al.  Brain‐Derived Neurotrophic Factor Protects Dopamine Neurons Against 6‐Hydroxydopamine and N‐Methyl‐4‐Phenylpyridinium Ion Toxicity: Involvement of the Glutathione System , 1992, Journal of neurochemistry.

[17]  R. Heavens,et al.  Decreased tyrosine hydroxylase mRNA but not cholecystokinin mRNA in the pars compacta of the substantia nigra and ventral tegmental area of aged rats. , 1993, Brain research. Molecular brain research.

[18]  P. Sanberg,et al.  Locomotion of aged rats: Relationship to neurochemical but not morphological changes in nigrostriatal dopaminergic neurons , 1993, Brain Research Bulletin.

[19]  J. Langston,et al.  Chronic intranigral administration of brain-derived neurotrophic factor produces striatal dopaminergic hypofunction in unlesioned adult rats and fails to attenuate the decline of striatal dopaminergic function following medial forebrain bundle transection , 1993, Neuroscience.

[20]  C. Gall,et al.  Dopaminergic neurons in rat ventral midbrain express brain‐derived neurotrophic factor and neurotrophin‐3 mRNAs , 1994, The Journal of comparative neurology.

[21]  D. Ingram,et al.  Behavioral assessment of aging in male Fischer 344 and Brown Norway rat strains and their F1 hybrid , 1994, Neurobiology of Aging.

[22]  M E Greenberg,et al.  Requirement for BDNF in activity-dependent survival of cortical neurons. , 1994, Science.

[23]  H. Phillips,et al.  Neurotrophic‐4/5 is a survival factor for embryonic midbrain dopaminergic neurons in enriched cultures , 1994 .

[24]  M. Beal,et al.  Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[25]  I. Fariñas,et al.  Targeted disruption of the BDNF gene perturbs brain and sensory neuron development but not motor neuron development , 1994, Cell.

[26]  S. Wiegand,et al.  Efficacy of Brain‐Derived Neurotrophic Factor and Neurotrophin‐3 on Neurochemical and Behavioral Deficits Associated with Partial Nigrostriatal Dopamine Lesions , 1994, Journal of neurochemistry.

[27]  H. Bradford,et al.  The response of human and rat fetal ventral mesencephalon in culture to the brain-derived neurotrophic factor treatment , 1994, Brain Research.

[28]  Rhonda,et al.  Overlapping and distinct actions of the neurotrophins BDNF, NT-3, and NT-4/5 on cultured dopaminergic and GABAergic neurons of the ventral mesencephalon , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[29]  Rudolf Jaenisch,et al.  Mice lacking brain-derived neurotrophic factor develop with sensory deficits , 1994, Nature.

[30]  Q. Yan,et al.  The biological responses of axotomized adult motoneurons to brain- derived neurotrophic factor , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[31]  L. Studer,et al.  Effect of BDNF on Dopaminergic, Serotonergic, and GABAergic Neurons in Cultures of Human Fetal Ventral Mesencephalon , 1995, Experimental Neurology.

[32]  C. Shults,et al.  BDNF attenuates the effects of intrastriatal injection of 6-hydroxydopamine , 1995 .

[33]  C. Altar,et al.  Brain-derived neurotrophic factor promotes the survival and sprouting of serotonergic axons in rat brain , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[34]  M. Levivier,et al.  Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[35]  R. Vejsada,et al.  Neuronal deficits, not involving motor neurons, in mice lacking BDNF and/or NT4 , 1995, Nature.

[36]  H. Hung,et al.  The mesolimbic dopaminergic pathway is more resistant than the nigrostriatal dopaminergic pathway to MPTP and MPP+ toxicity: role of BDNF gene expression. , 1996, Brain research. Molecular brain research.

[37]  M. D. Lindner,et al.  Alleviation of behavioral deficits in aged rodents following implantation of encapsulated GDNF-producing fibroblasts , 1996, Brain Research.

[38]  H. Thoenen,et al.  GABAergic Stimulation Regulates the Phenotype of Hippocampal Interneurons through the Regulation of Brain-Derived Neurotrophic Factor , 1996, Neuron.

[39]  Lawrence C. Katz,et al.  Opposing Roles for Endogenous BDNF and NT-3 in Regulating Cortical Dendritic Growth , 1997, Neuron.

[40]  G. Halliday,et al.  Specific A10 Dopaminergic Nuclei in the Midbrain Degenerate in Parkinson's Disease , 1997, Experimental Neurology.

[41]  B. Pakkenberg,et al.  Neocortical neuron number in humans: Effect of sex and age , 1997, The Journal of comparative neurology.

[42]  Quantifying operant behavior deficits in rats with bilateral 6-hydroxydopamine lesions of the ventrolateral striatum. , 1997, The Chinese journal of physiology.

[43]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[44]  G. Rozas,et al.  Drug-free evaluation of rat models of parkinsonism and nigral grafts using a new automated rotarod test , 1997, Brain Research.

[45]  S. Pomeroy,et al.  Abnormal Cerebellar Development and Foliation in BDNF −/− Mice Reveals a Role for Neurotrophins in CNS Patterning , 1997, Neuron.

[46]  J. Conner,et al.  Anterograde transport of brain-derived neurotrophic factor and its role in the brain , 1997, Nature.

[47]  J. Wehner,et al.  Defective Motor Behavior and Neural Gene Expression in RIIβ-Protein Kinase A Mutant Mice , 1998, The Journal of Neuroscience.

[48]  T. Hagg.  Neurotrophins Prevent Death and Differentially Affect Tyrosine Hydroxylase of Adult Rat Nigrostriatal Neuronsin Vivo , 1998, Experimental Neurology.

[49]  E. López-Martín,et al.  The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism , 1998, Journal of Neuroscience Methods.

[50]  F. Gage,et al.  Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[51]  E. Hirsch,et al.  Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra. , 1999, Neuroreport.

[52]  K. Seroogy,et al.  Expression of trkB and trkC mRNAs by adult midbrain dopamine neurons: A double‐label in situ hybridization study , 1999, The Journal of comparative neurology.

[53]  H. Ichinose,et al.  Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease , 1999, Neuroscience Letters.

[54]  Y. Barde,et al.  Brain‐Derived Neurotrophic Factor Levels in the Nervous System of Wild‐Type and Neurotrophin Gene Mutant Mice , 1999, Journal of neurochemistry.

[55]  F. Miller,et al.  Functionally Antagonistic Interactions between the TrkA and p75 Neurotrophin Receptors Regulate Sympathetic Neuron Growth and Target Innervation , 1999, The Journal of Neuroscience.

[56]  A. Sadikot,et al.  Characterization of dopaminergic midbrain neurons in a DBH:BDNF transgenic mouse , 1999, The Journal of comparative neurology.

[57]  N. Muzyczka,et al.  Prevention of 6-hydroxydopamine-induced rotational behavior by BDNF somatic gene transfer , 1999, Brain Research.

[58]  JaneR . Taylor,et al.  Enhancement of Locomotor Activity and Conditioned Reward to Cocaine by Brain-Derived Neurotrophic Factor , 1999, The Journal of Neuroscience.

[59]  T. Joh,et al.  Neuroprotection and Neuronal Differentiation Studies Using Substantia Nigra Dopaminergic Cells Derived from Transgenic Mouse Embryos , 1999, The Journal of Neuroscience.

[60]  N. Ward,et al.  BDNF Is Needed for Postnatal Maturation of Basal Forebrain and Neostriatum Cholinergic Neurons In Vivo , 2000, Experimental Neurology.

[61]  K. Unsicker,et al.  GDNF and NT-4 Protect Midbrain Dopaminergic Neurons from Toxic Damage by Iron and Nitric Oxide , 2000, Experimental Neurology.

[62]  G. Donnan,et al.  Reduced BDNF mRNA Expression in the Parkinson's Disease Substantia Nigra , 2000, Experimental Neurology.

[63]  G. M. Story,et al.  Evaluation of Nigrostriatal Dopaminergic Function in Adult +/+ and +/− BDNF Mutant Mice , 2001, Experimental Neurology.

[64]  A. Manning-Boğ,et al.  Environmental factors in Parkinson's disease. , 2002, Neurotoxicology.

[65]  E Vorontsova,et al.  Motor and associative deficits in D2 dopamine receptor knockout mice , 2002, International Journal of Developmental Neuroscience.

[66]  B. Lom,et al.  Local and Target-Derived Brain-Derived Neurotrophic Factor Exert Opposing Effects on the Dendritic Arborization of Retinal Ganglion Cells In Vivo , 2002, The Journal of Neuroscience.

[67]  B. Pakkenberg,et al.  Ageing of substantia nigra in humans: 
cell loss may be compensated by hypertrophy , 2002, Neuropathology and applied neurobiology.

[68]  Ichiro Kanazawa,et al.  Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms , 2002, Annals of neurology.

[69]  D. Dluzen,et al.  Striatal dopamine output is compromised within +/− BDNF mice , 2002, Synapse.

[70]  Y. Itoyama,et al.  Association between a polymorphism of brain‐derived neurotrophic factor gene and sporadic Parkinson's disease , 2003, Annals of neurology.

[71]  L. Stanford,et al.  Repetitive acute pain in infancy increases anxiety but does not alter spatial learning ability in juvenile mice , 2003, Behavioural Brain Research.

[72]  Bente Pakkenberg,et al.  Aging of the human cerebellum: A stereological study , 2003, The Journal of comparative neurology.

[73]  I. Whishaw,et al.  Distinct forelimb and hind limb stepping impairments in unilateral dopamine-depleted rats: use of the rotorod as a method for the qualitative analysis of skilled walking , 2003, Journal of Neuroscience Methods.

[74]  R. Pfeiffer,et al.  Modulation of Nigrostriatal Dopaminergic Transmission by Antisense Oligodeoxynucleotide Against Brain-Derived Neurotrophic Factor , 1998, Neurochemical Research.

[75]  R. Lister.  The use of a plus-maze to measure anxiety in the mouse , 2004, Psychopharmacology.

[76]  J. Campusano,et al.  Functional interactions between somatodendritic dopamine release, glutamate receptors and brain-derived neurotrophic factor expression in mesencephalic structures of the brain , 2004, Brain Research Reviews.

[77]  C. Dourish,et al.  Behavioural and pharmacological characterisation of the elevated “zero-maze” as an animal model of anxiety , 1994, Psychopharmacology.